Listen to this article
📖 < 1 min.

An additional section for scientific pre-clinical papers, in vitro studies of anti-cancer mechanisms, clinical trials with cancer. Examine the available facts of published research data. A section for information hungry enthusiasts.

1) Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways.

2) Unexpected Antitumorigenic Effect of Fenbendazole when Combined with Supplementary Vitamins.

3) Fenbendazole as a Potential Anticancer Drug.

4) The Anthelmintic Drug Mebendazole Induces Mitotic Arrest and Apoptosis by Depolymerizing Tubulin in Non-Small Cell Lung Cancer.

5) Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia.

6) Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis.

7) Benzimidazole as Novel Therapy for Hormone-Refractory Metastatic Prostate Cancer.

8) Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.

9) Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer.

10) Repurposing Drugs in Oncology (ReDO) — mebendazole as an anti-cancer agent.

11) Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy.

12) Chronic myelogenous leukemia in a great horned owl (Bubo virginianus)